The biopharmaceutical industry, in its relentless pursuit of innovation and efficiency, faces a silent but profound challenge: the erosion of…
Read More
Retatrutide eases sleep apnea and knee arthritis in new Phase 3 data, extending Lilly’s obesity lead over Novo
The Dawn of a New Era in Metabolic Disease Management The announcement at the ADA meeting highlighted retatrutide’s remarkable efficacy,…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s.
A significant stride in the realm of integrated medicine has been reported by Remepy, a pioneering startup, as its innovative…
Read More
Ginkgo, Tangible and Inductive Bio aim to move ADME decisions from lead optimization to hit ID
A significant paradigm shift is underway in the pharmaceutical industry’s approach to small-molecule drug discovery, as a new collaborative platform,…
Read More
Blazing new paths for biotech
The landscape for American biotechnology firms has undergone a profound transformation in recent years, shifting from a period of robust…
Read More
Boehringer Ingelheim eyes MASH as the next front for survodutide, a GLP-1/glucagon receptor dual agonist
Neeraja Balachander, who oversees Boehringer Ingelheim’s extensive cardio-renal-metabolic portfolio, articulated the company’s ambitious vision. “We have a program in MASH,…
Read More
ADA Conference Unveils Groundbreaking GLP-1 Advances Amidst Controversy Over Scientific Dissent
The annual scientific sessions of the American Diabetes Association (ADA) this week served as a pivotal platform for significant announcements…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
A decade in the making: How functional NAMs are redefining cardiac safety assessment
In recent years, the pharmaceutical industry has witnessed a dramatic acceleration in the adoption of New Approach Methodologies (NAMs) for…
Read More
GLP-1 Blockbusters Propel Pharma R&D Returns to 7%, Masking Broader Productivity Challenges, Deloitte Report Reveals
After a prolonged period where growth remained uneven in the wake of global disruptions, a pivotal metric for biopharma research…
Read MoreYOU MAY HAVE MISSED
